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1. Introduction 
According to the reports published by the American Cancer Society, an estimated 22,020 
cases of primary malignant tumors of brain and other central nervous system (CNS) sites 
were diagnosed in the United States in 2010 (Jemal et al. 2010, 277-300). During the same 
period, approximately 13,140 persons with these tumor types succumbed to their disease. 
Among adults, malignant brain tumors are estimated at 7.3 cases per 100,000 person-years, 
and in children 4.5 cases per 100,000 person-years (Maher and McKee 2010, 484-527). 
Malignant neoplasms of the brain and nervous system were estimated to have accounted for 
1.5% of all new cancer cases and 2.3% of cancer deaths in the United States in 2008, as 
reported in the SEER Cancer Statistics Review (Surveillance, Epidemiology, and End Results 
(SEER) Program, 
National Cancer Institute 1975-2005. www.seer.cancer.gov). Brain tumors aggregate in a 
bimodal age distribution pattern. The first occurs during infancy and early childhood 
between birth to 4 years of age, followed by a gradual rise in incidence after age 24, and a 
late second peak between 50–79 years of age. The Central Brain Tumor Registry of the 
United States reports that gliomas account for 36% of all primary brain tumors, and 81% of 
malignant tumors (CBTRUS Statistical Report 2008: Primary brain tumors in the United States. 
Central brain tumor registry of the United States, Chicago. www. cbtrus.org). Among these, 
glioblastoma multiforme (GBM) is the most common (Raizer 2011, 152-157), accounting for 
at least 50% of cases. Glioblastoma multiforme remains an incurable disease, with a 5 year 
survival rate ranging from around 13% for patients aged 15-45 years to only 1% for those 
aged 75 years and older (Surveillance, Epidemiology, and End Results (SEER) 2007, SEER* Stat 
software, version 6.3.5. www.seer.cancer.gov/seerstat/software).  
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Obstacles to cure of brain tumors include, among others, the juxtaposition of tumor and 
vital centres of normal brain, “blood brain barrier”(Armulik et al. 2010, 557-561; Blanchette 
and Fortin 2011, 447-463; Kalra and Couldwell 2011, 179-180), limitations in achieving 
complete tumor resection, lack of concordance in tumor classification (Daumas-Duport and 
Varlet 2003, 622-636), and inherent resistance of untreated tumor to chemotherapy (Eimer et 
al. 2011, 1017-1027; Denysenko et al. 2010, 343-351; Luqmani 2005, 35-48), and radiation 
therapy (Friedman et al. 2009, 199-209). Newer approaches to investigating the biology of 
gliomas is the first step towards more precise identification of their dynamic evolution, 
which in turn should lead to development of more effective therapeutic strategies and 
improved long term survival. 
2. Diagnosis of brain tumors 
The World Health Organisation (WHO) Classification of Tumors of the CNS lists astrocytic 
tumors as the most common among tumors of neuroepithelial (or glial) tissue. The “gold 
standard” of this classification is a histopathological diagnosis based on light microscopy 
examination of hematoxylin and eosin (H&E) stained biopsy tissue sections. Slides are 
scanned to record gradation of tumor cell density, vascularisation, small-cell density and 
matrix loosening. Histologic grading of astrocytomas range from the most benign form 
(grade I - pilocytic astrocytomas) to the most malignant (grade IV – glioblastoma 
multiforme), based on the degree of anaplasia, mitotic index, degree of invasion into 
surrounding tissue, microvascular proliferation, and foci of necrosis (Kleihues et al. 2002, 
215-25; Louis et al. 2007, 97-109). The term “multiforme” derives from the spectrum of 
different cell types and tissue heterogeneity observed within the tumor: astroblastic, 
oligodendroglial, and dedifferentiated cells in combination with anaplastic, gemistocytic, 
fibrillary, or pilocytic components (Iglesias-Rozas and Hopf 2005, 351-356).  
However, subjectivity in interpretation and ambiguities in definitions and histologic criteria 
in the WHO classification (Tanaka et al. 2011; Reifenberger and Wesseling 2010, 549-551), 
such as multiple phenotypes within the same tumor at one or different points in time 
(Hassler et al. 2006, 46-55; Walker et al. 2003, 4841-4851) as well as newly-evolving tumor 
variants (Kozak and Moody 2009, 833-841; Valle-Folgueral et al. 2008, 343-349; Martinez et 
al. 2007, 26-34) and unclassifiable tumors (Cenacchi and Giangaspero 2004, 185-192) 
emphasize the limitations of histological classification.  
Immunohistochemical stain panels provide more specific information regarding antigen 
expression associated with certain cell types, and also reflect patterns of genetic aberrations 
within tumors. These panels consist of a combination of immunoperoxidase stains and anti 
cellular-protein-specific monoclonal antibodies. Cytokeratins, vimentin, desmin, glial 
fibrillary acidic protein, and neurofilament protein stains serve to more accurately identify 
the cell lineage of tumors. In addition, immunocytochemical stains such as keratin, 
synaptophysin, S100, melanoma antigen recognized by T cells (MART-1), leukocyte 
common antigen (LCA), organic ion transporter 3/4 (OCT 3/4) and smooth muscle actin 
(SMA) provide a better definition in cases of less well-differentiated neoplasms (Wieczorek 
and Longtine 2010, 1-5). The advantage of these stains is that they can be used with paraffin-
embedded stored tissue samples. 
Increasingly, molecular biological and cytogenetic techniques are being used to investigate 
mechanisms of malignant transformation and to identify tumor markers predictive of 
behaviour and outcome (Martinez et al. 2007, 26-34; Krex et al. 2003, 1377-84). Aberrations 
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within the tumor genome have been detected by such molecular genetic techniques as 
fluorescent in-situ hybridisation, comparative genomic hybridisation (Wiltshire et al. 2000, 
164-173), spectral karyotyping (Zuber et al. 2002, 111-115) and gene expression profiling 
(Liang et al. 2005, 5814-5819). Newer variants of “classical” GBM including giant cell, small 
cell, epitheloid, and rhabdoid variants, as well as those containing PAS and trichrome stain-
positive intracellular inclusions, continue to manifest (Kleinschmidt-DeMasters et al. 2006, 
273-286). These evolutionary changes in the histopathological manifestations of GBM are 
reflected in the 2007 revision of the original 2002 WHO classification, where newer GBM 
variants such as GBM with an oligodendroglioma component have been recognized 
(Nakamura, Makino, and Kuratsu 2011). Tumor heterogeneity detected by the array of these 
diagnostic methods is a compelling reason for developing more refined and accurate 
recognition techniques. 
3. Fourier Transform (FTIR) Infrared Spectroscopy  
The challenges posed by heterogeneous (Bleau, Huse, and Holland 2009, 2936-2944) 
expressions of histological, cytogenetic, and oncogenetic mechanisms within brain tumors 
can be addressed by a relatively new biodiagnostic research tool, vibrational spectroscopy.  
Fourier Transform Infrared (FTIR) vibrational spectromicroscopy combines light 
microscopy with infrared spectroscopy. It uses mid-infrared light obtained from a 
conventional thermal source as a probe to characterise qualitative and quantitative 
vibrational properties of biological specimens at a molecular level. FTIR spectroscopy is 
both a chemical and a molecular probe. The infrared (IR) spectra generated by biological 
tissues are a composite display of vibrational shifts in covalent bonds, derived from their 
biomolecular content (proteins, lipids, sugars, and nucleic acids).  
The intensities of the spectra express quantitative information, while the frequencies at 
which they are displayed reflect qualitative information on the nature, composition, and 
relationships of their molecular structures. FTIR data can therefore be used as molecular 
“fingerprints” for correlation of spectral patterns with biological structure unique to normal 
tissues and their malignant counterparts. The technique of FTIR has the advantage of 
examining tissues “at the source” and not requiring any processing of the samples prior to 
testing. Scientists have capitalised on the finding that lipid, protein, carbohydrate and 
nucleic acid content of biological tissues can be precisely identified by specific spectral 
“signatures” generated when they are subjected to absorption spectroscopy using mid-
infrared (mid-IR) light (wave numbers 4000-1000 cm-1) (Marinkovic et al. 2002, 189-197). The 
amide I band (~1650 cm-1) results mainly from the (C=O) stretching vibrations of protein 
amide bonds. The amide II band ~ 1549 cm-1 arises from the d(N–H) bending and (C–N) 
stretching vibrations of amide bonds. The (C=O) stretching of lipids is displayed ~ 1740 
cm-1, and the anti-symmetric  (PO2-) stretching of nucleic acids and phospholipids ~ 1225 
cm-1.  
The precise frequency of absorption from a particular molecular bond or group is dependent 
on the environment in which it resides; specific changes within them characterise such 
conditions as skin cancer (McIntosh et al. 1999, 951-956). The commencement of 
transformation of normal tissues into a dysplastic state, and onwards to neoplasia, is most 
likely initiated at a subcellular level by molecular changes and subtle shifts in tissue 
components, amenable to detection by IR spectromicroscopy. The subtle changes in large 
numbers of spectra generated during biospectroscopy are prone to subjective error if 
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interpreted by inspection alone. This problem can be overcome by means of multivariate 
statistical analyses performed by specific software programs designed for this purpose. FTIR 
spectromicroscopy is proving to be a useful complementary tool for purposes of enhanced 
diagnostic accuracy, improved tumor grading, developing treatment strategies, and 
monitoring responses to therapy. 
3.1 Conventional FTIR - animal studies 
In a study using FTIR imaging of C6 gliomas grown in the brains of Wistar rats, researchers 
were able to differentiate between normal brain structures and tumor tissue; altered patterns 
were detected in the intermediate zones. FTIR transmission spectroscopy confirmed 
decreased concentrations of lipids within tumors, which was correlated to the degree of 
myelination present. The spectroscopic findings correlated with light microcopy detection of 
myelin in healthy brain tissues using Luxol fast blue and Luxol fast blue-cresyl stains 
(Amharref et al. 2006, 892-899). Reflection/absorption IR spectromicroscopy studies were 
conducted on autopsied formalin-fixed de-paraffinised tumor tissue sections of rat C6 
glioma allografted in Wistar rat brain. Spectral signatures from malignant tissue were 
compared with those of a normal control, and subjected to multivariate analyses. This 
allowed for generation of false-colour coded maps, comparing variations in lipoprotein 
composition. In contrast to the normal sample, tumor spectra displayed qualitative and 
quantitative variations in amide I and II bands pertaining to protein components (Bambery 
et al. 2006, 900-907). Another study with the same animal model and using transmission 
spectroscopy demonstrated several features of clinical relevance: i) spectral patterns of 
proteins and nucleic acids could be used to differentiate between normal, malignant, peri-
tumoral and necrotic brain tissues, ii) the development of tumor was marked by a reduction 
in total lipid content (cholesterol, phosphatidyletanolamine, phosphatidyl-choline, and 
galactocerebroside), and iii) glioma tissues contained a high amount of sphingomyelin, 
nucleic acids, and oleic acids (Beljebbar et al. 2008, 8406-8415).  
3.2 Conventional FTIR - human studies  
A proof of concept diagnostic study using IR spectroscopy to classify biopsy specimens of 25 
human brain tumors resulted in an overall 89% concordance with light microscopy re. WHO 
diagnosis and grading of astrocytic tumors (Steiner et al. 2003, 464-471). Researchers were 
able to identify changes within tumors in both the nature, and relative amounts, of brain 
lipids, including gangliosides and phospholipids. In view of the conundrum that 
conventional histological findings are not predictive of tumor behavior, correlation between 
histological diagnoses and FTIR spectroscopy was conducted in a few cases of human head 
and neck tumors (gingival squamous cell carcinoma and sarcomatoid carcinoma). In the 
former, high DNA, lipid and collagen components were detected; in the latter, similar 
findings also were documented, but in a heterogeneous distribution (Bruni et al. 2004, 19-
26). 
IR spectroscopy was used to differentiate normal brain from both in vitro glioblastoma cell 
lines as well as 56 tumor specimens from glioma patients. In normal control samples, 
molecular signatures demonstrated differences between white and grey matter, based on 
increased spectral endowments from lipids and cholesterol. As well, these researchers were 
able to demonstrate progressive decreases in brain lipids, inversely proportional to the 
degree of anaplasia (Krafft et al. 2004, 921-925). Characteristic IR spectral signatures of 
www.intechopen.com
 Synchrotron Radiation: Applications in Diagnosis and Treatment of Malignant Brain Tumors 345 
disparate tissue types from multiple tissue sections of two brain tumors were used to 
develop a multivariate classification model. The model was based on linear discriminant 
analysis (LDA) and used to classify single IR spectra from 51 patients. Results of analysis 
using the LDA model revealed 100% accuracy with normal brain tissue (5 samples), 80% 
accuracy for grade III astrocytomas (15 samples), and 74.2% accuracy for grade IV/GBM (31 
samples) (Krafft et al. 2006, 301-305). Extension of this methodology to the macroscopic 
imaging mode of three tumor sections of GBM from one patient resulted in spectra that 
were almost identical. However, when a supervised classification model based on the LDA 
algorithm was applied to the data, gradation of tumor content was suggestive of tissue 
sections being derived from intra-tumor, tumor margin, and extra-tumor locations 
respectively (Krafft et al. 2007, 1669-1677).  
Meningiomas comprise a group of brain tumors with significant risks of recurrence and 
unpredictable outcomes (Drummond, Zhu, and Black 2004, 113-130). We investigated, by 
means of mid-infrared reflectance spectromicroscopy, a number of meningiomas to 
determine their spectral signatures, and to more accurately differentiate tumor tissue from 
normal control (Ali et al. 2008, 297-301). Briefly, brain tumor samples were obtained at 
elective surgery from four patients with meningiomas. A sample derived from histologically 
proven normal brain tissue at the periphery of resected margins in one patient served  
as control. Paired tumor tissue sections 5 micrometres in thickness were cut in a cryostat at  
–20C. The first section was placed on a glass slide for H&E stain, and the section 
immediately was transferred onto an IR-reflective slide for spectromicroscopy. Concordance 
of tumor-bearing areas was achieved by means of a novel technique developed in our lab. It 
requires superimposing a digital tractile grid over paired H&E and IR tissue section images 
of tumor bearing areas within the tissue section that are demarcated by a pathologist, and 
then transferring matching grid coordinates onto the overview image generated by the 
spectromicroscope in the preparation of mid-IR spectroscopy (Figures 1a, 1b and 1c) (Ali et 
al. 2010, 857-860). 
 
 
1a      1b            1c 
Fig. 1. 1a. Equisized H&E stained tissue section with concordant grid and tumor-bearing 
area within digital boundaries (outlined in black). 1b. Equisized paired IR unstained tissue 
section showing tumor-bearing area (within red boundaries) with concordant grid and 
overlaid digital boundary map transferred from Figure 1a. Fig. 1c. Equisized 
spectromicroscopy overview image of tissue section with raster map (red square) outlined 
within tumor-bearing area (within red boundaries), in the preparation of mid-IR 
spectroscopy (note matched grid coordinates in all images).  
www.intechopen.com
 Diagnostic Techniques and Surgical Management of Brain Tumors 346 
Mid-IR microscopy data collection: Thin tumor section on the IR reflectance slide was raster 
scanned using Globar light-sourced spectromicroscopy at the Canadian Light Source (CLS) 
synchrotron facility. Spectromicroscopy was performed using an IFS 66v/S FTIR 
spectrometer with a conventional light source attached to a Hyperion IR microscope with a 
15X Cassegrain objective and a single channel MCT detector. Raster scans were obtained in 
the mid-infrared range of 4000-900 cm-1 using a 50 micrometres x 50 micrometres aperture, 
25 micrometres step size, 32 scans per step, and resolution of 4 cm-1. Stage control, data 
collection and processing were done using OPUS software and analysed using CytoSpec, a 
software tool designed for FTIR image analysis. Visible images were obtained using a 
charged-couple device camera, which was linked to the infrared images. 
 
 
2a      2b 
 
2c      2d 
Fig. 2. Comparison of average mid-IR spectra of brain tissue samples, control and tumour in 
the spectral region of 4000-2600 cm-1 and 1900-900 cm-1. 2a,b: Control spectrum (black) and a 
cluster from the tumour tissue (red). 2c,d: Control spectrum (black) and two clusters from 
the tumour tissue(red and blue). Despite similar spectra pattern in 2a-d, the following 
important points are noted. i) The relative CH2 and CH3 stretching intensities labeled as 1 
and 2, respectively in 2a and 2c that represent lipid peaks are very different. ii) the peak A at 
1735 cm-1 shows a large decrease in lipid  concentrations in the tumour samples., iii) the 
peak B at 1655 cm-1 in 2c indicates the amide I peak in the tumour sample is largely 
unchanged from the control sample. This peak in 2d shifts towards 1631 cm-1, iv) the peak C 
at 1548 cm-1 in 2c that represents protein amide II is largely unchanged from the control 
sample but this peak in 2d shifts slightly to 1544 cm-1, and v) the peak D at 1515 cm-1 
corresponds to tyrosine amidic linkage. 
www.intechopen.com
 Synchrotron Radiation: Applications in Diagnosis and Treatment of Malignant Brain Tumors 347 
The average spectra shown in Figures 2a-d compare two different brain tissue samples, 
control and tumor, each from a different patient.  
The first, most striking difference occurs in the bands associated with lipids, particularly 
unsaturated fatty acids, demonstrating a marked decrease in all the clusters associated with 
tumor tissue. In particular, the bands at 3010, 2920, 2850, and 1735 cm-1 are all weaker than 
in the control spectra. More subtle differences are visible in the region between 1900-900 
cm1, particularly the among the protein bands. The amide I band of the control tissue shows 
a large proportion of undifferentiated proteins and a small contribution of α-helical proteins 
at 1655 cm-1. The tumor tissue samples tend more towards undifferentiated proteins; 
however, some of the clusters show an increased beta-sheet band at 1631 cm-1. A band 
associated with the amino acid tyrosine at 1515 cm-1 is generally more pronounced in the 
tumor samples than in the control samples. In the spectral region of 1500-900 cm-1, the 
tumour samples shows very weak peak intensities compared to control. 
The results to date indicate the presence of a unique signature that could help identify 
tumor tissue. The marked diminution of the bands associated with the lipids combined with 
subtle changes in the main protein bands seems to be an indicator that a sample tissue is 
derived from tumor. This fingerprint is similar for all the different samples studied to date, 
and it may be possible to refine this spectral fingerprint to detect to a specific tumour class. 
Comparable results were found in three other patients with meningiomas. One of the 
strengths of the study is that, in spite of small numbers, all four patients had the same type 
and grade of tumor confirmed by a pathologist. This avoided the potential problem arising 




Fig. 3. SOLEIL synchrotron facility near Paris, France (Copyright © Synchrotron Soleil, 
reproduced with permission). 
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Fig. 4. Schematic diagram of Synchrotron Soleil. The circular ring is the synchrotron, a 
particle accelerator that brings electrons to very high speeds. The synchrotron emits 
"synchrotron radiation", especially X-rays; these are sent into the various beamlines (the 
straight lines branching out of the synchrotron). Each beamline contains scientific 
instruments, experiments etc. and receives an intense beam of radiation (Copyright © 
EPSIM 3D/JF Santarelli, Synchrotron Soleil, reproduced with permission). 
4. Synchrotron 
A synchrotron is a large ring-shaped particle accelerator into which electrons are fed from a 
smaller booster ring and a linear accelerator. The magnetic fields to turn the electrons, and 
electric fields to accelerate them within the main booster ring, are carefully synchronised 
with the electrons as they travel in a circular orbit at nearly the speed of light. The 
acceleration of electrons to this very high speed causes them to lose energy when they turn 
in magnetic fields. The energy is lost by emitting photons (light energy or electromagnetic 
radiation), which are then transported along tangential steel pipes called beamlines. The 
photon transport involves mirrors and devices for focusing and tuning the light for a 
particular use. The entire spectrum of electromagnetic radiation including, among others, 
(IR) Infrared light and monochromatic high energy x-ray beams, can be selectively extracted 
from photons within a given beamline and used for diagnostic and therapeutic applications 
(Figure 5).  
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Fig. 5. Experimental hutch, 01B1-1 Mid-Infrared Spectromicroscopy beamline, Canadian 
Light Source, Saskatoon, Canada. Dotted arrows indicate pathway of synchrotron mid-IR 
beam entering spectrometer, passing through the tumour specimen, and generating the 
spectra. a. FTIR Spectrometer, b. spectromicroscope, c. unstained thin tumor section, d. 
spectra displayed on screen (author’s files).  
4.1 Synchrotron FTIR spectroscopy  
Conventional thermal IR spectromicroscopy examination of biological tissues has limited 
spatial resolution, arising from low brightness diffraction or optical aberrations, including 
insufficient spatial resolution of only approximately 20-25 micrometres (Carr 2001, 1613). 
This problem is overcome by synchrotron IR light by virtue of its brightness, which is 100–
1000 times greater than that from a conventional source (Miller and Dumas 2006, 846-857). 
Individual biological cells range from 5-30 micrometres in diameter, too small for probing 
by conventional IR sources. The much greater brightness of synchrotron-sourced light, 
however, permits intracellular imaging of molecular chemical structure and, compared to 
thermal IR light sources, provides greater spectroscopic detail and serves as a more refined 
diagnostic tool (Holman et al. 2002, 417-424) for a spectrum of malignant brain tumors, both 
in terms of differentiating tumor types as well as assessing degrees and patterns of 
anaplasia.  
Figure 6 shows two absorbance spectra collected from 10 x 10 mm areas of the same region 
of a single tissue section. The upper trace was recorded using a synchrotron source, and the 
lower trace using a conventional thermal source. Each spectrum was collected for 1024 scans 
at 8 cm-1 spectral resolution. The advantage of the synchrotron as an infrared light source at 
high spatial resolution can clearly be seen in the difference between the spectra. The 
spectrum collected using the thermal source shows particularly high levels of “noise” in the 
fingerprint region below 1600 cm-1 (Tobin et al. 2004, 27-39). 
It has become increasingly clear that synchrotron IR spectromicroscopy is an extremely 
valuable analytical tool when determining the chemical composition of biological and 
biomedical samples, at the diffraction-limited spatial resolution. Highly resolved IR 
spectromicroscopy, together with the high signal-to-noise level of recorded spectra, is 
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essential in generating chemical and statistically-derived multivariate images. Synchrotron 
IR spectromicroscopy is very useful because of the achievable diffraction-limited spatial 
resolution, for the high signal-to-noise spectra obtained even with a diffraction-limited spot 
size, and for rapid data acquisition. Details of the secondary (alpha-helix) structure of 
proteins and their intracellular distribution can be identified with much greater clarity, 
allowing detailed analysis because of good spectral quality. The synchrotron source 
provides the necessary brightness to fulfill this requirement in the case of individual cells 
(Dumas et al. 2004, 289-302).  
 
 
Fig. 6. Absorption spectra of tissue sample recorded under identical collection conditions 
using a thermal infrared source (lower trace) and synchrotron radiation (upper trace). 
(Copyright © The Royal Society of Chemistry, reproduced with permission) 
Our diagnostic experiments progressed from using thermal light-sourced mid-IR reflectance 
spectromicroscopy to synchrotron light-sourced transmission spectromicroscopy to study 
human GBM tumor samples (Ali et al. 2010, 11-16). Tumor tissue was obtained from six 
patients with GBM and control samples from two other non-malignant patients. 
Experimental procedures were the same as for the meningioma study described earlier, with 
the following changes: The second of thin, paired tissue sections was mounted onto a CaF2 
slide for mid-IR transmission spectromicroscopy at the 01B1-1 beamline, Canadian Light 
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Source (CLS). Transmission spectromicroscopy was performed using a 36X Cassegrain 
objective and a single channel MCT detector. Raster scans were obtained in the range of 
4000-900 cm-1 using a 10 x 10 micrometres aperture, 10 micrometres step size, 32 scans per 
step, and resolution of 4 cm-1. A multivariate statistical analysis was performed after 
converting all spectra to their second derivative and subjecting them to hierarchical cluster 
analysis (HCA). Pseudo-color maps based on cluster analysis were then created by 
assigning a color to each spectral cluster. 
A total of 16 raster maps of GBM tumour tissue specimens from 6 patients were obtained 
and the results compared with 7 maps of control brain tissue specimens from resection 
margins of two patients, one with craniopharyngioma and the other with astrocytic gliosis. 
A study pathologist confirmed normal brain tissue on histopathological examination of the 
two control samples. The average spectra of GBM and normal control tissues were 
generated using synchrotron-sourced mid-IR beamline at CLS  (Figure 7) 
 
 




Fig. 7. Comparison of average mid-IR spectra of GBM and control sample in the region of 
3,800-2,600 (7a) and 1,900-900 cm-1 representing acyl vibrations fatty acids, peptide linkages 
of proteins, phosphodioxy groups of nucleic acids (7b) and the figure 7c depicts striking 
differences in the average spectra of GBM tumour and normal tissue in the spectral range of 
3,100-2,600 cm-1, representing lipid CH2 and CH3 stretching intensities. 
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8a      8b 
Fig. 8. Spectromicroscopic infrared mapping of tissue sections. False color codes represent 
varying tissue composition. 8a. Control, specimen displays four different clusters of spectra 
representing different tissue components. Blue and green pixels represent lipid and protein 
respectively; yellow & red pixels indicate nucleic acid components. 8b. GBM, displays 
marked reduction in lipid component. 
The coloured cluster map representing control tissue (Figure 8a) clearly reflects four 
groupings of chemical moieties in normal brain tissue, including lipids, proteins, and 
nucleic acids. Blue pixels indicating lipid predominate; green and red pixel clusters indicate 
protein and DNA respectively. By contrast, in a GBM tumor sample (Figure 8b); lipid 
content is reduced drastically while protein content comprises the major portion of the 
image. 
Data obtained from spectral comparisons of tumor and control samples graphically display 
spatial distribution of cluster groups representing different tissue components. Figure 9 
demonstrates false colour images displaying the spatial distribution of clusters from our 
experiments. Five clusters were considered for both control and tumour tissues. Each cluster 
was assigned a false color code for comparison purposes. The images in Figures 9a and 9b, 
representing control and GBM specimens respectively, clearly differentiate between the 
spatial distribution of the various clusters identified by the hierarchical cluster analysis 
(HCA) algorithm (Ward’s algorithm). In GBM tumour samples, the cluster representing red 
pixels, most likely lipid, has been significantly reduced, while clusters identified by green 
pixels predominate, compared to control sample. These false colour cluster images 
demonstrate the sensitivity of these HCA method techniques in displaying subtle 
differences not obvious on visual inspection alone. A number of significant differences in 
the mid-IR spectral patterns of have been identified in GBM tumours compared to normal 
brain tissue. These differences could serve as diagnostic molecular spectral “signatures” in 
identifying residual GBM within tumour resection margins. A further study with larger 
number of patient samples for precise identification of a molecular signature unique to GBM 
has corroborated the spectral signatures identified in our pilot study (manuscript in 
preparation).  
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9a      9b 
Fig. 9. Hierarchical (HCA) cluster analysis of (9a) control specimen and (9b) GBM tumor 
specimen. HCA false color image of 5 clusters displaying diversity in tissue composition of 
tumor tissue compared to control (see below). 
4.2 Synchrotron Microbeam Radiation Therapy (MRT) 
Curative management of human brain tumors is dependent upon accuracy of histological 
diagnosis and grading, achieving tumor-free margins during surgical removal, and 
inclusion of residual macroscopic and microscopic tumor within radiation therapy fields 
(Mason et al. 2007, 110-117) (Brem et al. 2011, 352-400). Obstacles to cure of a highly 
anaplastic tumor like GBM include inability to achieve complete tumor resection because of 
its rapid growth and invasive properties, migration of GBM cells several centimeters away 
from the primary tumor and even into the contralateral cerebral hemisphere (Lefranc, 
Brotchi, and Kiss 2005, 2411-2422), and its inherent resistance to radiation therapy and 
chemotherapy (Kemper et al. 2004, 415-423). Newer, innovative, and more precisely-
targeted treatment approaches are required to positively impact on survival.  
One of the limiting factors in delivery of curative radiation therapy to cancer patients is the 
dose-limiting tolerance of normal tissues (Deman et al. 2010, 586-589). There are several 
promising treatment approaches (Clarke, Butowski, and Chang 2010, 279-283) aimed at 
increasing the survival rate for patients with GBM tumors. One such therapy is microbeam 
radiation therapy (MRT), which has been designed for the specific purpose of maximising 
tumoricidal dose delivery while sparing surrounding normal tissues (Regnard et al. 2008, 
861-878; Dilmanian et al. 2006, 9709-9714; Nettelbeck et al. 2009, 447-456; Serduc et al. 2009, 
6711-6724; Prezado et al. 2009, 4897-4902).  
Synchrotron-generated parallel, planar, micrometre-wide X-ray beams (microbeams) have 
been shown to safely deliver significantly higher than normal doses to the cerebella of 
weaning piglets without obvious neurological deficit one year later (Figure 10) (Laissue et 
al. 2007, 577-581). Histopathological examination at autopsy revealed preservation of normal 
cerebellar architecture except for thin, white horizontal parallel stripes approximately 20-30 
micrometres in width, corresponding to the path of the microbeams. Degenerative changes 
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in neurons and astroglial cells were noted only along the tracks of the microbeams; no tissue 
necrosis, hemorrhage or demyelination were noted by light microscopy. This leads the way 
for MRT as a potential tool to treat brain tumors in young children, whose CNS is still in the 
developmental stages and therefore vulnerable to compromise of neurocognitive functions. 
 
 
Fig. 10. Cerebellum of a piglet about 15 months after irradiation (skin entrance dose 300 Gy); 
hematoxylin/eosin-stained horizontal tissue section. Tissue has maintained its normal 
architecture. This white horizontal parallel stripes, clearly visible in inset, correspond to 
paths of approximately 27 µM-wide microbeam; beam spacing was about 210 µM 
(Copyright © Developmental Medicine & Child Neurology, reproduced with permission)  
The concept of MRT is similar to GRID therapy (Tenzel 1952, 399-408; Huhn et al. 2006, 607-
612; Mohiuddin et al. 1999, 721-727) in that healthy tissue is spared by applying discretely 
spaced beams as opposed to a continuous solid beam over the same volume. With MRT, 
several narrow beams tens of micrometres in width, spaced hundreds of micrometres apart, 
are delivered through the tumor. With high dose rates, these beams have been shown to 
preferentially kill glioblastoma tumors while better sparing the healthy brain tissues 
(Deman et al. 2010, 586-589; Sheleg et al. 2002, 53-59; Miura et al. 2006, 71-75; Dilmanian et 
al. 2003, 632-641). Although the mechanism of action of MRT remains to be elucidated, there 
are indications that the vasculature damaged by MRT is more readily repaired in healthy 
tissue than in glioblastoma tumors. This purported repair mechanism is felt to be dependent 
on differential regenerative activity of capillary endothelial cells in spared tissues in 
between the microbeams. Until now, MRT research has been carried out primarily at a 
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limited number of international synchrotron facilities. The main advantage of a synchrotron-
derived radiation source is a very high dose rate, at least several hundred Gy per second, 
which allows for near instantaneous treatment times. This is important when dealing with 
micrometre-sized beams. If treatment times are drawn out, the energy deposited by the 
microbeams is spread out due to vascular pulsations and organ motion. Another advantage 
of a synchrotron source is that it is essentially nondivergent. This allows for the production 
of very flat minibeam profiles with little offaxis fall off. Nondivergent beams also yield a 
sharper penumbra on the individual minibeams, which in turn yields lower valley doses. 
While awaiting validation of proven safety and efficacy, synchrotron MRT treatment studies 
to date have been restricted to in vitro and in vivo pre-clinical experiments, mostly with brain 
tumors grown in small animals.  
In preparation for synchrotron MRT experiments, we designed and created a minibeam 
collimator for minibeam radiation therapy studies in rodents using a 250 kVp clinical X-ray 
machine as a simulated synchrotron source (Babcock et al. 2011, 2192-2197). Our research 
has been designed to lead up to pre-clinical studies using synchrotron MRT. We have 
established an animal model of GBM xenografts grown in brains of immunocompromised 
nude mice, and plan to commence studies at the Biomedical Imaging and Therapy (BMIT) 
beamline 05B1-1 at the Canadian Light Source (CLS). The CLS is Canada’s national 
synchrotron facility, located on campus at the University of Saskatchewan (Wysokinski et al. 
2007, 73-76).  
A treatment strategy designed to overcome limitations in tissue radiation tolerance was 
studied in a rat F98 glioma model. Test animals with implanted brain tumor were treated 
with a synergistic combination of single dose beam synchroton radiation, simultaneous with 
an infusion of an iodinated contrast agent. The results were compared with two other 
control groups: untreated tumor-bearing rats, and those treated with synchrotron radiation 
therapy alone. A 20% and 44% increase in life spans were noted in the rats irradiated 
without or with iodine, respectively, albeit a modest one in terms of days of prolongation of 
life (median survival times of 12.5, 15 and 18 days for untreated controls, irradiated without 
iodine, or with iodine respectively)(Adam et al. 2003, 1413-1426). The research group 
developed a strategy aimed at disrupting the blood-brain barrier to increase delivery of 
iodinated contrast agent into F98 rat gliomas.  
The blood-brain barrier (BBB) is an integrated physiological system composed of 
interdigitating endothelial cells supported by pericytes, astrocytes and extracellular matrix, 
as well as enzymes, and transporters, working in concert to maintain homeostasis of the 
extracellular milieu. In so doing, it impedes the transport of chemotherapeutic agents across 
the vascular compartment into the CNS matrix. Osmotic disruption of the BBB is achieved 
by administration of hypertonic solutions such as mannitol, which induce crenation of the 
endothelial cells, disruption of their tight interdigitations, and enhanced diffusion of drugs 
across the BBB (Kemper et al. 2004a, 415-423). In principle, osmotic disruption of the BBB 
should allow for increased deposition of radiosensitising agents within tumor, thereby 
increasing the total lethal dose of intra-tumoral irradiation following external beam 
radiation treatment.  
In the next series of experiments in F98 glioma-bearing rats were treated with synchrotron 
stereotactic radiotherapy (SSR) in a single dose fraction, simultaneous with intravascular 
infusion (intra-arterial or intravenous) of a combination of iodinated contrast agent and 
mannitol. The latter drug was added to induce temporary BBB disruption and thereby allow 
greater deposition of photoactive contrast within the tumor while it was being irradiated. 
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Percentage increase in life span (ILS) was most significant (169%) in rats who received both 
SSR and combined drugs via intra-arterial (i.e., intra-carotid) administration for X-ray doses 
≤ 15 Gy. Administration via the intravenous route of the same drug combination 
concomitant with SSR resulted in 116% ILS, while no benefit was noted (91% ILS) in the 
group treated with SSR only. Of interest is the fact that at 25 Gy dose, survival advantage 
was greatest in the group that was treated with SSR alone (Adam et al. 2006, 603-611). 
Furthering the above studies, a platinum derivative, cis-Platinum (CDDP), was chosen to 
explore the synergistic effect of platinum compounds reported in human studies. 
Interestingly, this pioneering study (Biston et al. 2004, 2317-2323) showed more than twice 
the amount of double-strand breaks (DSB’s) when mouse models were treated with a 
combination of CDDP and synchrotron beam radiation with energy in the vicinity of 
platinum K-edge. The study also correlated survival benefit compared to other energy 
beams.  
Realisation that modulation of energy of electromagnetic beams given in combination with 
compounds that achieve supra-additive tumor ablation (De Stasio et al. 2006, 206-213), while 
sparing normal tissues, creates possibilities for ambitious research undertakings. Further 
understanding of this as yet unchartered territory will pave the way for developing novel 
treatment methods resulting in enduring control of these tumors. 
5. Conclusions  
Histological grading of tumors delineates a continuum from least to most malignant (grade 
I-IV, respectively). Gradations of malignancy, as well as variations in tumor type, may be 
identified in a single tissue section. The challenge for the pathologist lies in accurately 
identifying the tumor and assessing the degree of anaplasia in order to guide the clinician 
with information to optimise treatment strategy and obtain a favourable outcome.  
Malignant tumors can be considered reverse versions of their tissues of origin, endowed 
with the ability to continually evolve their cellular structure and extracellular matrix in 
response to changes in their microenvironment. Diagnostic light microscopy examination 
and immunohistochemical stains identify events “frozen” at one point in time, i.e., when the 
tumor is biopsied or excised. As we begin to consider and understand tumors more as 
dynamic entities, our approach to studying their biologic behavior by conventional static 
diagnostic methodologies is increasingly being supplemented by biochemical, molecular 
genetic, and cell signaling probes. IR spectroscopy serves as a light probe, penetrating 
tissues and cells at a molecular level, in real time, to provide a composite display of the 
chemical composition and molecular structural relationships of tissues and individual cells.  
The brilliant intensity of synchrotron-generated light energy, a form of electromagnetic 
radiation, reveals nuances of tumor tissue activity at a subcellular or molecular level. It 
“illumines” our minds to the understanding that tissues, normal and malignant, even when 
completely severed from the body, can still dance to a rhythm of inherent vibrations that 
identifies them as unique. Another form of synchrotron-sourced electromagnetic radiation, 
microbeam radiations, proves a tool for improved eradication of malignant tumors, which 
are themselves none other than condensed forms of electromagnetic radiations. Thus, in the 
domain of brain tumors, the synchrotron serves a triple purpose as a diagnostic, treating, 
and teaching tool. 
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